Summary
This report provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for optic neuropathy, glaucoma, Leber’s hereditary optic neuropathy (LHON) and optic neuritis, and features dormant and discontinued products.
Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 10 products in development for this indication.
Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye. There are 13 products in development for this indication.
LHON is an inherited form of vision loss. This condition usually begins in a person’s teens or twenties. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 16 products in development for this indication.
Optic neuritis refers to inflammation of the optic nerve. Symptoms include pain, vision loss, dyschromatopsia (impaired ability to perceive colors) and flashing lights. There are 12 products in development for this indication.
Molecular targets acted on by products in development for optic nerve disorders include kinases, growth factors and cannabinoid receptors. Companies operating in this pipeline space include NicOx SA Regeneron Pharmaceuticals and Amgen.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
'
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 4
1.2 List of Figures 8
2 Introduction 9
2.1 Optic Nerve Disorders Report Coverage 9
2.2 Optic Neuropathy - Overview 9
2.3 Glaucoma - Overview 9
2.4 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Overview 9
2.5 Optic Neuritis - Overview 9
3 Therapeutics Development 10
3.1 Optic Neuropathy 10
3.2 Glaucoma 13
3.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 24
3.4 Optic Neuritis 28
4 Therapeutics Assessment 31
4.1 Optic Neuropathy 31
4.2 Glaucoma 37
4.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 47
4.4 Optic Neuritis 52
5 Companies Involved in Therapeutics Development 58
5.1 Optic Neuropathy 58
5.2 Glaucoma 60
5.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 91
5.4 Optic Neuritis 97
6 Dormant Projects 101
6.1 Optic Neuropathy 101
6.2 Glaucoma 102
6.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 106
6.4 Optic Neuritis 107
7 Discontinued Products 108
7.1 Optic Neuropathy 108
7.2 Glaucoma 108
7.3 Optic Neuritis 110
8 Product Development Milestones 111
8.1 Optic Neuropathy 111
8.2 Glaucoma 117
8.3 Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 128
8.4 Optic Neuritis 143
9 Appendix 146
9.1 Methodology 146
9.2 Coverage 146
9.3 Secondary Research 146
9.4 Primary Research 146
9.5 Expert Panel Validation 146
9.6 Contact Us 147
9.7 Disclaimer 147
1.1 List of Tables
Table 1: Number of Products under Development for Optic Neuropathy 10
Table 2: Number of Products under Development by Companies, Optic Neuropathy 11
Table 3: Number of Products under Development by Universities/Institutes, Optic Neuropathy 12
Table 4: Products under Development by Companies, Optic Neuropathy 12
Table 5: Products under Development by Universities/Institutes, Optic Neuropathy 13
Table 6: Number of Products under Development for Glaucoma 13
Table 7: Number of Products under Development by Companies, Glaucoma 14
Table 8: Number of Products under Development by Universities/Institutes, Glaucoma 17
Table 9: Products under Development by Companies, Glaucoma 18
Table 10: Products under Development by Universities/Institutes, Glaucoma 23
Table 11: Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 24
Table 12: Number of Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 25
Table 13: Number of Products under Development by Universities/Institutes, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 26
Table 14: Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 26
Table 15: Products under Development by Universities/Institutes, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 27
Table 16: Number of Products under Development for Optic Neuritis 28
Table 17: Number of Products under Development by Companies, Optic Neuritis 29
Table 18: Number of Products under Development by Universities/Institutes, Optic Neuritis 30
Table 19: Products under Development by Companies, Optic Neuritis 30
Table 20: Products under Development by Universities/Institutes, Optic Neuritis 30
Table 21: Number of Products by Stage and Target, Optic Neuropathy 32
Table 22: Number of Products by Stage and Mechanism of Action, Optic Neuropathy 33
Table 23: Number of Products by Stage and Route of Administration, Optic Neuropathy 35
Table 24: Number of Products by Stage and Molecule Type, Optic Neuropathy 36
Table 25: Number of Products by Stage and Target, Glaucoma 38
Table 26: Number of Products by Stage and Mechanism of Action, Glaucoma 41
Table 27: Number of Products by Stage and Route of Administration, Glaucoma 45
Table 28: Number of Products by Stage and Molecule Type, Glaucoma 47
Table 29: Number of Products by Stage and Target, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 48
Table 30: Number of Products by Stage and Mechanism of Action, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 50
Table 31: Number of Products by Stage and Route of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 51
Table 32: Number of Products by Stage and Molecule Type, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 53
Table 33: Number of Products by Stage and Target, Optic Neuritis 54
Table 34: Number of Products by Stage and Mechanism of Action, Optic Neuritis 56
Table 35: Number of Products by Stage and Route of Administration, Optic Neuritis 57
Table 36: Number of Products by Stage and Molecule Type, Optic Neuritis 59
Table 37: Optic Neuropathy - Pipeline by Amgen Inc, H2 2018 60
Table 38: Optic Neuropathy - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018 61
Table 39: Optic Neuropathy - Pipeline by Quark Pharmaceuticals Inc, H2 2018 61
Table 40: Optic Neuropathy - Pipeline by Regenera Pharma Ltd, H2 2018 62
Table 41: Optic Neuropathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018 62
Table 42: Glaucoma - Pipeline by AC Immune SA, H2 2018 63
Table 43: Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H2 2018 63
Table 44: Glaucoma - Pipeline by Allergan Plc, H2 2018 64
Table 45: Glaucoma - Pipeline by Altacor Ltd, H2 2018 64
Table 46: Glaucoma - Pipeline by Amarantus Bioscience Holdings Inc, H2 2018 65
Table 47: Glaucoma - Pipeline by Amgen Inc, H2 2018 65
Table 48: Glaucoma - Pipeline by Annexon Inc, H2 2018 66
Table 49: Glaucoma - Pipeline by Astellas Pharma Inc, H2 2018 66
Table 50: Glaucoma - Pipeline by Bial - Portela & Ca SA, H2 2018 67
Table 51: Glaucoma - Pipeline by BioAxone BioSciences Inc, H2 2018 67
Table 52: Glaucoma - Pipeline by Can-Fite BioPharma Ltd, H2 2018 68
Table 53: Glaucoma - Pipeline by Cellix Bio Pvt Ltd, H2 2018 68
Table 54: Glaucoma - Pipeline by Certa Therapeutics Pty Ltd, H2 2018 68
Table 55: Glaucoma - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018 69
Table 56: Glaucoma - Pipeline by D. Western Therapeutics Institute Inc, H2 2018 70
1.2 List of Figures
Figure 1: Number of Products under Development for Optic Neuropathy 10
Figure 2: Number of Products under Development by Companies, Optic Neuropathy 11
Figure 3: Number of Products under Development for Glaucoma 13
Figure 4: Number of Products under Development by Companies, Glaucoma 14
Figure 5: Number of Products under Development by Universities/Institutes, Glaucoma 17
Figure 6: Number of Products under Development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 24
Figure 7: Number of Products under Development by Companies, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 25
Figure 8: Number of Products under Development for Optic Neuritis 28
Figure 9: Number of Products under Development by Companies, Optic Neuritis 29
Figure 10: Number of Products by Top 10 Targets, Optic Neuropathy 31
Figure 11: Number of Products by Stage and Top 10 Targets, Optic Neuropathy 31
Figure 12: Number of Products by Top 10 Mechanism of Actions, Optic Neuropathy 32
Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Optic Neuropathy 33
Figure 14: Number of Products by Routes of Administration, Optic Neuropathy 34
Figure 15: Number of Products by Stage and Routes of Administration, Optic Neuropathy 34
Figure 16: Number of Products by Molecule Types, Optic Neuropathy 35
Figure 17: Number of Products by Stage and Molecule Types, Optic Neuropathy 36
Figure 18: Number of Products by Top 10 Targets, Glaucoma 37
Figure 19: Number of Products by Stage and Top 10 Targets, Glaucoma 37
Figure 20: Number of Products by Top 10 Mechanism of Actions, Glaucoma 40
Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Glaucoma 41
Figure 22: Number of Products by Routes of Administration, Glaucoma 44
Figure 23: Number of Products by Stage and Routes of Administration, Glaucoma 45
Figure 24: Number of Products by Top 10 Molecule Types, Glaucoma 46
Figure 25: Number of Products by Stage and Top 10 Molecule Types, Glaucoma 46
Figure 26: Number of Products by Targets, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 47
Figure 27: Number of Products by Stage and Targets, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 48
Figure 28: Number of Products by Mechanism of Actions, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 49
Figure 29: Number of Products by Stage and Mechanism of Actions, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 49
Figure 30: Number of Products by Routes of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 50
Figure 31: Number of Products by Stage and Routes of Administration, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 51
Figure 32: Number of Products by Molecule Types, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 52
Figure 33: Number of Products by Stage and Molecule Types, Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) 52
Figure 34: Number of Products by Targets, Optic Neuritis 53
Figure 35: Number of Products by Stage and Targets, Optic Neuritis 54
Figure 36: Number of Products by Mechanism of Actions, Optic Neuritis 55
Figure 37: Number of Products by Stage and Mechanism of Actions, Optic Neuritis 55
Figure 38: Number of Products by Routes of Administration, Optic Neuritis 56
Figure 39: Number of Products by Stage and Routes of Administration, Optic Neuritis 57
Figure 40: Number of Products by Molecule Types, Optic Neuritis 58
Figure 41: Number of Products by Stage and Molecule Types, Optic Neuritis 58
